

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension: Erratum

In the article, “A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension”,^[1] which appeared in Volume 99, Issue 32 of *Medicine*, Figure 5 was originally published with extra labels on the scheduled time axes (morning and afternoon/evening). This has been updated in the published version.

Reference

- [1] Wiu J, Du X, Lv Q. A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension. *Medicine*. 99;32:e21465.

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Wiu J, Du X, Lv Q. A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension: Erratum. *Medicine* 2020;99:36(e22168).

<http://dx.doi.org/10.1097/MD.00000000000022168>